학술논문
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Document Type
Article
Author
Yu, Evan Y ; Petrylak, Daniel P; O'Donnell, Peter H; Lee, Jae-Lyun; van der Heijden, Michiel S; Loriot, Yohann; Stein, Mark N; Necchi, Andrea; Kojima, Takahiro; Harrison, Michael R; Hoon Park, Se; Quinn, David I; Heath, Elisabeth I; Rosenberg, Jonathan E; Steinberg, Joyce; Liang, Shang-Ying; Trowbridge, Janet; Campbell, Mary; McGregor, Bradley; Balar, Arjun V
Source
In The Lancet Oncology June 2021 22(6):872-882
Subject
Language
ISSN
1470-2045